(0.30%) 5 115.49 points
(0.31%) 38 357 points
(0.33%) 15 981 points
(-0.87%) $83.12
(5.77%) $2.03
(0.38%) $2 356.20
(0.50%) $27.67
(4.04%) $959.35
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $5.09
発行日: 14 2月 2024 @ 23:30
リターン: -3.93%
前回のシグナル: 2月 13 - 03:37
前回のシグナル:
リターン: -0.97 %
Live Chart Being Loaded With Signals
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS)...
Stats | |
---|---|
本日の出来高 | 96 264.00 |
平均出来高 | 262 866 |
時価総額 | 132.15M |
EPS | $0 ( 2024-02-13 ) |
次の収益日 | ( $-0.340 ) 2024-06-26 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.650 |
ATR14 | $0.0170 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Rotunno Mary L. | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Gin Jerry B | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Fitzpatrick Margaret M | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Curley Joanne | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Cunningham Ann Michelle | Buy | 12 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.56 |
Last 94 transactions |
Buy: 11 348 392 | Sell: 716 774 |
ボリューム 相関
VistaGen Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
ADXN | 0.836 |
SHYF | 0.828 |
SRRK | 0.827 |
FLUX | 0.822 |
PRAX | 0.821 |
LILAK | 0.819 |
LILA | 0.816 |
PXLW | 0.816 |
TNXP | 0.816 |
FOXA | 0.805 |
10 最も負の相関 | |
---|---|
FEYE | -0.808 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
VistaGen Therapeutics Inc 相関 - 通貨/商品
VistaGen Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $-227 300 |
総利益: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2023 |
収益: | $-227 300 |
総利益: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2022 |
収益: | $1.11M |
総利益: | $293 700 (26.49 %) |
EPS: | $-7.24 |
FY | 2021 |
収益: | $1.09M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.208 |
Financial Reports:
No articles found.
VistaGen Therapeutics Inc
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。